Please wait a minute...
文章检索
预防医学  2025, Vol. 37 Issue (12): 1222-1227    DOI: 10.19485/j.cnki.issn2096-5087.2025.12.007
  论著 本期目录 | 过刊浏览 | 高级检索 |
身体形态指数和身体圆度指数预测非肥胖人群非酒精性脂肪性肝病的效果比较
吴梓敬1,2, 李纪新2, 邱林杰2, 任燕2, 李美洁2, 邹姹姹1,2, 张晋2
1.北京中医药大学研究生院,北京 100029;
2.中国中医科学院西苑医院,北京 100091
Comparison of the value of a body shape index and body roundness index in predicting non-alcoholic fatty liver disease among non-obese population
WU Zijing1,2, LI Jixin2, QIU Linjie2, REN Yan2, LI Meijie2, ZOU Chacha1,2, ZHANG Jin2
1. Graduate School of Beijing University of Chinese Medicine, Beijing 100029, China;
2. Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China
全文: PDF(930 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 比较身体形态指数(ABSI)、身体圆度指数(BRI)预测非肥胖人群非酒精性脂肪性肝病(NAFLD)的效果,为早期识别NAFLD高危人群提供参考。方法 选择2022—2024年在中国中医科学院西苑医院参加健康体检且体质指数<28 kg/m2的成人为调查对象,收集人口学信息、疾病史、身高、体重、腰围、血压和血脂指标等,计算ABSI和BRI;采用腹部超声诊断NAFLD。采用多因素logistic回归模型分析ABRI、BRI与非肥胖人群NAFLD的关系,采用广义加性模型结合惩罚样条法拟合平滑曲线,识别非线性关系,通过阈值效应确定拐点;采用受试者操作特征(ROC)曲线评估ABSI、BRI预测非肥胖人群NAFLD风险效果。结果 调查1 195人,其中男性345人,占28.87%;女性850人,占71.13%。检出非肥胖人群NAFLD 348例,检出率为29.12%。NAFLD组和非NAFLD组的调整后ABSI(sABSI)分别为7.95±0.33和8.08±0.34,BRI分别为3.35±0.79和4.15±0.64,差异有统计学意义(均P<0.05)。多因素logistic回归分析结果显示,校正人口学信息、疾病史、血压和血脂指标等因素后,sABSI(OR=1.932,95%CI:1.184~3.158)、BRI(OR=1.594,95%CI:1.071~2.360)与非肥胖人群NAFLD存在统计学关联。sABSI、BRI与非肥胖人群NAFLD呈非线性正相关,当sABSI≤8.46、BRI≥2.72时,两者与非肥胖人群NAFLD呈正相关。ABSI、BRI预测非肥胖人群NAFLD风险的ROC曲线下面积分别为0.619和0.782,最佳截断值分别为0.082和3.656。结论 ABSI、BRI与非肥胖人群NAFLD呈非线性关系,BRI预测非肥胖人群NAFLD风险效果较好,可作为非肥胖人群NAFLD早期识别的辅助指标。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
吴梓敬
李纪新
邱林杰
任燕
李美洁
邹姹姹
张晋
关键词 身体形态指数身体圆度指数非酒精性脂肪性肝病非肥胖人群    
AbstractObjective To compare the value of a body shape index (ABSI) and body roundness index (BRI) in predicting non-alcoholic fatty liver disease (NAFLD) among non-obese population, so as to provide a reference for the early identification of populations at high risk of NAFLD. Methods Adults with a body mass index (BMI) of less than 28 kg/m2 who underwent health check-ups in Xiyuan Hospital of China Academy of Chinese Medical Sciences from 2022 to 2024 were selected as the study subjects. Demographic information, disease history, height, weight, waist circumference, blood pressure, and blood lipid indicators were collected, and ABSI and BRI were calculated. NAFLD was diagnosed using abdominal ultrasound. A multivariable logistic regression model was employed to analyze the relationships between ABSI, BRI and NAFLD among non-obese population. A generalized additive model combined with the penalized spline method was used to fit smooth curves to identify nonlinear relationships, and threshold effects were utilized to determine inflection points. The values of ABSI and BRI in predicting NAFLD among non-obese population were used the receiver operating characteristic (ROC) curve. Results A total of 1 195 individuals were surveyed, including 345 males (28.87%) and 850 females (71.13%). A total of 348 cases of NAFLD were detected among the non-obese population, with a detection rate of 29.12%. The adjusted ABSI (sABSI) in the NAFLD group and non-NAFLD group were 7.95±0.33 and 8.08±0.34, while the BRI were 3.35±0.79 and 4.15±0.64, respectively, with statistically significant differences between the two groups (both P<0.05). Multivariable logistic regression analysis showed that, after adjusting for demographic information, disease history, blood pressure, and blood lipid indicators, both sABSI (OR=1.932, 95%CI: 1.184-3.158) and BRI (OR=1.594, 95%CI: 1.071-2.360) were significantly associated with NAFLD among non-obese population. Nonlinear positive correlations were observed between sABSI, BRI, and NAFLD among non-obese population. When sABSI≤8.46 and BRI≥2.72, both indices were positively associated with NAFLD. The area under the ROC curve for ABSI and BRI in predicting NAFLD risk among non-obese population were 0.619 and 0.782, respectively, with optimal cut-off values of 0.082 and 3.656, respectively. Conclusions ABSI and BRI show a non-linear relationship with NAFLD among non-obese population. BRI demonstrates relatively better performance in predicting NAFLD risk among this population and can serve as an auxiliary indicator for the early identification of NAFLD among non-obese population.
Key wordsa body shape index    body roundness index    non-alcoholic fatty liver disease    non-obese population
收稿日期: 2025-09-10      修回日期: 2025-11-30      出版日期: 2025-12-10
中图分类号:  R575.5  
基金资助:北京中医药“薪火传承3+3”项目(2023-SZ-A51); 国家重点研发计划项目子课题(2018YFC20006004); 中国中医科学院科技创新工程(CI2021A03005); 中国中医科学院西苑医院具有知识产权的医疗机构制剂和中药新药的研发与转化专项任务(XYZY0301-16)
作者简介: 吴梓敬,硕士研究生在读,中医内科学专业
通信作者: 张晋,E-mail:jin_zhang2000@hotmail.com   
引用本文:   
吴梓敬, 李纪新, 邱林杰, 任燕, 李美洁, 邹姹姹, 张晋. 身体形态指数和身体圆度指数预测非肥胖人群非酒精性脂肪性肝病的效果比较[J]. 预防医学, 2025, 37(12): 1222-1227.
WU Zijing, LI Jixin, QIU Linjie, REN Yan, LI Meijie, ZOU Chacha, ZHANG Jin. Comparison of the value of a body shape index and body roundness index in predicting non-alcoholic fatty liver disease among non-obese population. Preventive Medicine, 2025, 37(12): 1222-1227.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2025.12.007      或      http://www.zjyfyxzz.com/CN/Y2025/V37/I12/1222
[1] NASSIR F.NAFLD:mechanisms,treatments,and biomarkers[J/OL].Biomolecules,2022,12(6)[2025-11-30] .https://doi.org/10.3390/biom12060824.
[2] BYRNE C D,TARGHER G.NAFLD:a multisystem disease[J].J Hepatol,2015,62(Suppl. 1):47-64.
[3] RIAZI K,AZHARI H,CHARETTE J H,et al.The prevalence and incidence of NAFLD worldwide:a systematic review and meta-analysis[J].Lancet Gastroenterol Hepatol,2022,7(9):851-861.
[4] ROJANO A,SENA E,MANZANO-NUÑEZ R,et al.NAFLD as the metabolic hallmark of obesity[J].Intern Emerg Med,2023,18(1):31-41.
[5] YE Q,ZOU B Y,YEO Y H,et al.Global prevalence,incidence,and outcomes of non-obese or lean non-alcoholic fatty liver disease:a systematic review and meta-analysis[J].Lancet Gastroenterol Hepatol,2020,5(8):739-752.
[6] ZHANG Z Y,ZHANG L,JIANG W Y,et al.Non-obese NAFLD had no better cardio-metabolic risk profile than obese NAFLD in type 2 diabetic patients[J/OL].Cardiovasc Diabetol,2022,21(1)[2025-11-30] .https://doi.org/10.1186/s12933-022-01648-9.
[7] 李明哲,杜娟,王晶晶.身体形态指数ABSI和身体圆度指数BRI的发展与应用[J].现代预防医学,2022,49(21):3968-3973,3985.
LI M Z,DU J,WANG J J.Development and application of body shape index(ABSI)and body roundness index (BRI)[J].Mod Prev Med,2022,49(21):3968-3973,3985.(in Chinese)
[8] RADMEHR M,HOMAYOUNFAR R,DJAZAYERY A.The relationship between anthropometric indices and non-alcoholic fatty liver disease in adults:a cross-sectional study[J/OL].Front Nutr,2024[2025-11-30] .https://doi.org/10.3389/fnut.2024.1494497.
[9] 中华人民共和国国家卫生健康委员会医政司.肥胖症中国诊疗指南(2024年版)[J].协和医学杂志,2025,16(1):90-108.
Department of Medical Administration,National Health Commission of the People's Republic of China.Chinese guidelines for the clinical management of obesity(2024 edition)[J].Med J Peking Union Med Coll Hosp,2025,16(1):90-108.(in Chinese)
[10] KRAKAUER N Y,KRAKAUER J C.A new body shape index predicts mortality hazard independently of body mass index[J/OL].PLoS One,2012,7(7)[2025-11-30] .https://doi.org/10.1371/journal.pone.0039504.
[11] THOMAS D M,BREDLAU C,BOSY-WESTPHAL A,et al.Relationships between body roundness with body fat and visceral adipose tissue emerging from a new geometrical model[J].Obesity,2013,21(11):2264-2271.
[12] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版)[J].临床肝胆病杂志,2018,34(5):947-957.
National Workshop on Fatty Liver and Alcoholic Liver Disease,Chinese Society of Hepatology,Chinese Medical Association,Fatty Liver Expert Committee,Chinese Medical Doctor Association.Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update[J].J Clin Hepatol,2018,34(5):947-957.(in Chinese)
[13] OGURTSOVA K,GUARIGUATA L,BARENGO N C,et al.IDF diabetes Atlas:Global estimates of undiagnosed diabetes in adults for 2021[J/OL].Diabetes Res Clin Pract,2022,183[2025-11-30] .https://doi.org/10.1016/j.diabres.2021.109118.
[14] 王援军,王倩,张婕,等.体检痩型非酒精性脂肪性肝病人群特征分析[J/OL].中国肝脏病杂志(电子版),2025,17(1):57-63.
WANG Y J,WANG Q,ZHANG J,et al.The characteristics of lean non-alcoholic fatty liver disease in physical examination[J/OL].Chin J Liver Dis Electron Version,2025,17(1):57-63.(in Chinese)
[15] ALMOMANI A,KUMAR P,ONWUZO S,et al.Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis,hepatocellular carcinoma,and cardiovascular outcomes in the United States:a population-based study and review of literature[J].J Gastroenterol Hepatol,2023,38(2):269-273.
[16] AHMAD HOSSEINI S,SHAYESTEH A A,HASHEMI S J,et al.The association between healthy eating index-2015 with anthropometric,cardiometabolic and hepatic indices among patients with non-alcoholic fatty liver disease[J/OL].BMC Gastroenterol,2024,24(1)[2025-11-30] .https://doi.org/10.1186/s12876-024-03222-x.
[17] SOLTANIEH S,SALAVATIZADEH M,POUSTCHI H,et al.The association of dietary inflammatory index(DII)and central obesity with non-alcoholic fatty liver disease(NAFLD)in people with diabetes(T2DM)[J/OL].Heliyon,2023,9(3)[2025-11-30] .https://doi.org/10.1016/j.heliyon.2023.e13983.
[18] YUAN M Q,HE J,HU X,et al.Hypertension and NAFLD risk:Insights from the NHANES 2017-2018 and Mendelian randomization analyses[J].Chin Med J,2024,137(4):457-464.
[19] EN L C E,ANG C Z,QUEK J,et al.Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus:an updated systematic review and meta-analysis[J].Gut,2023,72(11):2138-2148.
[1] 陆凤, 徐彬, 庞丽丽. 瘦型非酒精性脂肪性肝病的影响因素分析[J]. 预防医学, 2024, 36(11): 953-957.
[2] 罗平平, 诸伟红, 邹菁, 丁洁霞. 非酒精性脂肪性肝病患者疾病感知及影响因素分析[J]. 预防医学, 2022, 34(3): 222-226.
[3] 唐英琪, 李英, 田坚. 2型糖尿病患者合并非酒精性脂肪性肝病的影响因素分析[J]. 预防医学, 2021, 33(3): 292-294.
[4] 周瑞芬, 杜秋菊, 姚国萍, 束龙, 郑培奋. 杭州市45~69岁人群非酒精性脂肪性肝病与2型糖尿病相关性研究[J]. 预防医学, 2020, 32(8): 809-812.
[5] 汪凌霄, 李勇杰, 李红. 2型糖尿病患者非酒精性脂肪性肝病与性激素水平的关系[J]. 预防医学, 2016, 28(12): 1221-1225.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed